Henna–curcumin ointment to prevent capecitabine hand–foot syndrome

MS-N166 · Traditional topical botanical · Hand–foot syndrome prevention · Breast or gastrointestinal cancer · Triple-blind pilot trial · Appraised 28 October 2026

Can a topical henna–curcumin ointment prevent capecitabine-induced hand–foot syndrome?

Evidence at a glance

Evidence label: Primary prevention result negative
Benefit: The ointment did not significantly reduce hand–foot syndrome grade across four chemotherapy courses; a post-hoc analysis suggested delayed onset.
Certainty: Low. This was a pilot trial, and the favorable timing analysis was post hoc after the main comparison was negative.
Risk: Topical henna and curcumin can cause irritation or allergy. Products sold as “black henna” may contain sensitizing adulterants and are not equivalent to the studied ointment.

What was studied

Ninety people with breast or gastrointestinal cancer were included in a randomized, triple-blind, placebo-controlled pilot. The Alpha ointment contained Lawsonia inermis 3 g and Curcuma longa 0.15 g per 30 g. It was applied to palms and soles twice daily from the first day of capecitabine for four treatment courses. WHO hand–foot syndrome grade was assessed.

What the evidence found

Median WHO hand–foot syndrome grade did not differ significantly between ointment and placebo during follow-up (P>0.05). Both groups worsened over time. A post-hoc analysis suggested later onset or deterioration with the ointment, but this was not the primary result. A separate within-person henna study also found no significant difference in development time or severity.

How to interpret it

This formulation did not prevent hand–foot syndrome in the primary analysis. A delayed-onset signal is not enough to recommend routine use, and topical symptom care does not affect tumor response or capecitabine efficacy.

Practical safety context

Do not apply unverified henna, especially “black henna,” to damaged skin. Stop for burning, blistering or spreading rash. Hand–foot syndrome may require capecitabine dose interruption or modification; topical products should not delay reporting pain or functional limitation.

Questions for the care team

Is the product pure henna–curcumin or an unverified commercial dye?
What grade of hand–foot syndrome requires a capecitabine dose change?
Which standard moisturizers, urea creams or mechanical precautions should I use?

Funding and conflicts

The full-text report described the study as a pilot; funding and author conflicts were not fully verified for this appraisal.

Sources

Last literature search: 28 October 2026. Record appraisal: 28 October 2026. This page is educational and does not replace individualized medical advice. Symptom, biomarker or observational findings must not be interpreted as proof of tumor control, recurrence prevention or longer survival unless those outcomes were directly tested.